CBLB was evaluated as a candidate gene for type 1 diabetes (T1D) susceptibility based on its association with autoimmunity in animal models and its role in T-cell costimulatory signaling. Cblb is one of the two major diabetes predisposing loci in the Komeda diabetes-prone (KDP) rat. Cbl-b, a ubiquitin ligase, couples TCR-mediated stimulation with the requirement for CD28 costimulation, regulating T-cell activation. To identify variants with possible effects on gene function as well as haplotype tagging polymorphisms, the human CBLB coding region was sequenced in 16 individuals with T1D: no variants predicted to change the amino-acid sequence were identified. Seven single-nucleotide polymorphism (SNP) markers spanning the CBLB gene were genotyped in multiplex T1D families and assessed for disease association by transmission disequilibrium testing. No significant evidence of association was obtained for either individual markers or marker haplotypes.
Introduction
Type I diabetes (T1D) arises from autoimmune destruction of the insulin-secreting b-cells of the pancreas requiring insulin replacement therapy for survival. T1D is a multifactorial disorder with contributions from multiple genetic and environmental components. 1 There is intense interest in the identification of these risk factors both for their potential benefits in understanding specific pathology of T1D and the more general insights they might provide into mechanisms of human autoimmunity. In T1D, considerable effort has been expended on linkage studies in affected sib pairs as an approach to identify genetic risk factors. [2] [3] [4] [5] [6] However, most successes in the identification of susceptibility loci have come from the testing of candidate genes for allelic association with the disease. Two regions, the HLA region on chromosome 6p and the insulin gene region on 11p, are generally accepted as containing T1D susceptibility loci, designated IDDM1 and IDDM2, respectively. Both of these regions were initially investigated based on the presence of viable candidate genes. 7, 8 Recently, a third susceptibility locus, the CTLA4 gene, which may play a more generalized role in autoimmunity, has been proposed based on its effects on T-cell costimulation, linkage studies in human T1D families and studies in the NOD mouse model of T1D. 9, 10 In the current study, we have evaluated another candidate T1D gene, CBLB, which is implicated based on studies in another animal model of T1D, the Komeda diabetes-prone (KDP) rat. The KDP rat model of autoimmune diabetes is characterized by a rapid onset of disease, but without the sex difference that characterizes the NOD mouse, or the lymphopenia that is characteristic of the BB rat.
11 KDP rats also exhibit additional autoimmune phenotypes that include lymphocyte infiltration into the thyroid gland, adrenal, kidney and pituitary. 10 Two loci, MHC and Cblb, have been shown to account for the major part of the disease risk in this model. 11, 12 A nonsense mutation in the Cblb gene of the KDP rat results in the production of a truncated Cbl-b protein lacking 484 amino acids.
As a member of the ubiquitin ligase family of proteins, Cbl-b participates in the degradation and trafficking of proteins. Studies in cell lines derived from Cblb À/À mice indicate that Cbl-b is a negative regulator of TCR signaling. Activation of naive wild-type CD4 T cells requires stimulation through both CD3 and CD28. Naïve Cblb À/À T cells display comparable levels of proliferation and IL2 secretion when stimulated through CD3 alone. Thus, elimination of Cbl-b alleviates the requirement for CD28 costimulation in T-cell activation, and can rescue the T-cell proliferation defect in cd28 À/À mice. 13, 14 Loss of the requirement for CD28 costimulation allows activation of naïve T cells in the periphery under conditions where they should be unresponsive, creating the potential for autoimmunity. Effects on T-cell costimula-tion are also implicated in T1D pathogenesis by reports, suggesting that CTLA-4 is involved in T1D susceptibility in both human and the NOD mouse. 9, 10, 15 Results and discussion All exons and flanking intronic regions of CBLB were sequenced in 16 unrelated T1D affected individuals to identify variants of possible functional significance and common SNPs that could serve as haplotype tags for association testing. In total, 17 variants were detected by sequencing, but none were judged likely to have an impact on CBLB function or expression ( Table 1) . Examination of the NCBI and Celera SNP databases revealed that nine of these polymorphisms were novel. Two rare missense mutations listed in the databases, P522S and R964W, were not detected.
Seven SNPs were selected from those identified by sequencing, and from the NCBI and Celera databases, based on their having minor allele frequencies greater then 0.20 and relatively even spacing across the gene (Figure 1a,b) . These SNPs were genotyped in T1D multiplex families. The number of families genotyped for different markers varied from 147 to 259. All seven markers had similar heterozygosities, between 0.34 and 0.41, and all were in Hardy-Weinberg equilibrium (P40.05). Intermarker linkage disequilibrium (LD) analyses revealed the presence of one large LD block of at least 101 kbp as defined by standardized disequilibrium coefficient D 0 40.8 ( Figure 1c ). This LD block included most of CBLB, from exon 5-18 and was bordered by the markers CBLB6 and CBLB2. Within this block, three haplotypes composed of alleles at five markers, CBLB2/ CBLB10/CBLB4/CBLB11/CBLB6, accounted for 85.8% of all the observed haplotypes: TGCCC (40.4%), GATTT (34.2%) and GACTT (11.2%). Indeed, even with the inclusion of the marker CBLB13, which does not fall within the LD block based on the stringent criteria used, four haplotypes accounted for the majority (90.9%) of all haplotypes observed in the CBLB region.
Association analysis, using TDT, 20 was performed using data for individual markers, as well as for two-, three-, four-and five-marker haplotypes. None of the individual markers displayed any significant association with T1D (Table 2 ). Three haplotypes, most notably that composed of the 'C' allele at CBLB4 and the 'A' allele at CBLB1 (35% of 61 transmissions, P ¼ 0.017) were significantly undertransmitted to affected offspring. However, none of these effects remained significant after correction for the number of tests performed.
The Cblb gene is mutated in the KDP rat model of T1D and transgenic rescue experiments confirm the pathogenic role of this mutation. 12 Functional studies of the product of the Cblb gene in knockout mice and cell lines derived from such mice indicate that Cbl-b plays a key role in T-cell costimulation. 13, 14 Defects in this signaling pathway that reduce the requirement for costimulation in T-cell activation are associated with autoimmunity. Knockouts of Cblb result in generalized autoimmunity, while the hypomorphic allele in the KDP rat, in the context of a permissive MHC allele, results in organspecific autoimmunity directed primarily against the pancreatic islets, but also against the thyroid gland, adrenal, kidney and pituitary. Recent studies implicate polymorphic variation affecting the threshold level of Tcell costimulation as playing a role in T1D susceptibility in both human and NOD mice. 9, 10, 15 These considerations led us to evaluate human CBLB as a possible candidate gene for human T1D susceptibility.
Since human T1D appears to be much more genetically complex than the diabetes occurring in the KDP rat, it is probably not surprising that resequencing in 16 individuals (32 chromosomes) revealed no obviously inactivating alleles. While deeper resequencing might reveal rare Sequencing of all exons and flanking intronic sequences (50-100 nucleotides) was performed on amplified genomic DNA samples from 16 unrelated T1D patients using Big Dye V3.1 (Perkin Elmer Applied Biosystems) and an ABI3100 capillary sequencer. CBLB gene and type 1 diabetes R Kosoy et al functional variants in CBLB, their apparent infrequency suggests that they are not likely to be major contributors to T1D susceptibility in human populations.
Despite the failure to detect clear functional variants by resequencing, there could exist common variants that have modest effects on transcription, splicing or stability, located outside of coding regions. Accordingly, we genotyped SNP markers spanning CBLB and evaluated them both for the extent of intermarker LD and for association to T1D. Much of the gene, including three of the four functional domains (RING finger, proline-rich domain and the leucine-zipper/ubiquitin-associated domain) were contained within a region of strong LD. However, none of the markers tagging common haplotypes in this region provided any significant evidence of association with T1D. These data provide little support for a functional role of variation in the CBLB gene in T1D susceptibility. The first three exons, and possibly the fourth as well, were outside of the strong LD block, but one marker, CBLB13, was positioned in the vicinity of the three first exons, while CBLB6 was positioned close to the fourth exon. Lack of association with alleles at CBLB13, either individually or as part of a haplotype, did not suggest a role for Nterminal coding sequences or the promoter of CBLB in T1D predisposition. Knowledge of the haplotype structure in the CBLB gene region and the identities of potential haplotype-tagging SNPs should facilitate the evaluation of the role of this critical gene in other autoimmune disorders. Characteristics of SNPs genotyped in T1D families. Genotyping was performed using either primer extension with fluorescence polarization detection, as described 16 or single-strand conformation polymorphism (SSCP). 17 (c) Linkage disequilibrium relationships between the genotyped SNP markers. Haplotype distributions were estimated using SIMWALK2. 18 Standardized disequilibrium coefficients (D 0 ) were calculated using GOLD. TDT analyses were performed using GENEHUNTER 21 for individual markers, as well as for two-, three-, four-, and five-marker haplotypes. Only results from individual markers are shown. For each marker, genotyping was performed in 147-259 nuclear families each with two unaffected parents and two T1D-affected offspring. Disease onset was less than 30 years of age in all affected individuals. Families were all of Caucasian European ancestry, ascertained within the US, and all DNA samples were obtained from the Human Biological Data Interchange (HBDI). 
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